06:01 AM EDT, 04/27/2026 (MT Newswires) -- Medtronic plc MDT unveiled interim data from its Sphere-9 catheter trial showing 65.5% of patients were free from ventricular tachycardia, or VT, recurrence at six months, the company said on Saturday.

The data was presented at the 2026 Heart Rhythm Society Annual Meeting.

In response to the clinical results and the unmet need in VT care, the US FDA granted Breakthrough Device Designation for the Sphere-9 catheter and approved a US pivotal trial.

Sphere-360 data showed 100% lesion durability, highlighting "consistency across patients with varied anatomies,"the company said.

Medtronic added that it has begun enrolling patients in the Conquer-AF trial to evaluate the Sphere-9 catheter in repeat atrial fibrillation procedures across the US, Europe and Australia.